Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Stilla Technologies Raises €20M in Series B Round

Stilla Technologies Raises €20M in Series B Round

Feb 11, 2020
|
staff reporter

NEW YORK – Stilla Technologies announced on Tuesday that it has raised €20 million ($22 million) in a Series B funding round.

The round includes a new investor, China-based TUS-Holdings. Stilla will use the funds to support development of a next-generation digital PCR platform and to expand in Asia.

In addition to TUS-Holding, funding in the round came from the firm's existing investors including Illumina Ventures, Kurma Partners, LBO France, Paris Saclay Seed Funds, BNP Paribas Développement, and Idinvest Partners.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

This Time, Novavax

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

New York's Own Review

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Shortened Visas for Some Students

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

Science Papers Examine Y Chromosomes of Archaic Humans, Schistosomiasis Therapeutic Targets

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Sep
30
Featured Webinar

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
01
Featured Webinar

Immune Repertoire Sequencing to Uncover SARS-CoV-2-Specific T Cell Responses and Dynamics

Sponsored by
Adaptive Biotechnologies

T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, and also support the development of antibodies by B cells. 

Oct
08
Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Sponsored by
Genecentric

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct
14
Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Sponsored by
Inivata

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

What's Popular?

In PCR

  1. Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

  2. BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

  3. Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

    Premium

  4. Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

  5. NIH Awardee MatMaCorp Developing SARS-CoV-2 Molecular Test for Rural Hospitals

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.